Pelthos Therapeutics, Inc. (PTHS)
24.73
-0.27
(-1.08%)
USD |
NYAM |
Aug 28, 16:00
24.46
-0.27
(-1.09%)
After-Hours: 20:00
Pelthos Therapeutics Gross Profit Margin (Quarterly) : 68.40% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 68.40% |
| March 31, 2026 | 70.91% |
| Date | Value |
|---|---|
| December 31, 2025 | 69.23% |
| September 30, 2025 | 54.31% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Travere Therapeutics, Inc. | 96.22% |
| ACADIA Pharmaceuticals, Inc. | 90.81% |
| Alnylam Pharmaceuticals, Inc. | 76.88% |
| Anika Therapeutics, Inc. | 65.15% |
| Savara, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -390.2% |
| Return on Assets | -79.92% |
| Return on Invested Capital | -147.2% |
| Profit Margin (Quarterly) | -150.1% |
| Operating Margin (Quarterly) | -111.0% |
| Return on Net Operating Assets | -97.05% |